Pharmacokinetics and Pharmacodynamics of Linezolid Continuous and Intermittent Administration
NCT ID: NCT05801484
Last Updated: 2023-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2022-07-01
2024-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Subject inclusion criteria:
A minimum of 30 subjects in each group will be included in the study, in accordance with the study inclusion criteria:
* patients hospitalized in the intensive care unit,
* female or male sex,
* age over 18 years,
* linezolid is prescribed by the attending physician, in empirical or targeted treatment
Exclusion criteria:
Patients who have documented severe liver failure (Child-Pugh C score). Patients who refuse to sign the informed consent
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Population Pharmacokinetics of Linezolid
NCT01200654
Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia
NCT01805284
Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia
NCT04531332
Beta-lactam Pharmacokinetics in Secondary Care
NCT03033394
Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients
NCT02993575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will take place on the Intensive Care Unit of University Clinical Municipal Hospital from Cluj-Napoca, Romania. The analysis of blood drug concentration will be carried out at University of Medicine and Pharmacy 'Iuliu Hatieganu', Pharmacokinetics and Biopharmacy Laboratory, from Cluj-Napoca, Romania.
The objectives of the study are:
* Determination and the comparison of the pharmacokinetic and pharmacodynamic parameters of linezolid administration following intermittent infusion or continuous infusion, in critically ill patients.
* Determination of the minimum inhibitory concentrations (MIC) for linezolid for the identified bacteria (Staphylococcus aureus, Coagulase-Negative Staphylococcus, Enterococcus spp., Streptococcus pneumoniae).
The study will be conducted in the ICU Department of the Municipal Clinical Hospital in Cluj-Napoca, Romania, following an open, prospective, randomized design, with two groups of patients (group with intermittent infusion and group with continuous infusion of the same daily dose of linezolid). The patients that will be included in each group will be the patients in need of intensive care who are prescribed linezolid by the attending physician, as empirical or targeted therapy.
Given the low light stability of the linezolid solution, the infusion bag will be protected with an opaque cover provided by the manufacturer throughout the infusion period. The administration will be carried out with the help of an infusomate.
The duration of the therapy will be established, for each patient, by the attending physician depending on the type, location and severity of the infection in accordance with the recommendations of the therapeutic guidelines.
Throughout the duration of the study, the subjects will receive the treatment according to the recommendations of the attending physician, regardless of the group they belong to, the only difference between the groups refers to the type of infusion used to administer linezolid.
Blood samples (10 samples) will be taken from each volunteer, according to the following schedule: immediately before the start of the infusion (T0) and at 1, 2, 4, 8, 12, 18, 24, 36, 48 hours from initiation of drug infusion. Then, a single daily sample will be taken until the end of the treatment. Blood samples will be used to determine plasma concentrations of linezolid.
The efficacy and safety of the treatment will be evaluated using clinical and paraclinical data which will be correlated with the pharmacokinetic parameters determined for each type of treatment (continuous infusion or intermittent infusion). The data will be recorded in a case report form without disclosing the identity of the patients (each patient will receive a code at the beginning of the study).
Each subject will be followed until discharge or a maximum of 30 days after initiation of therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Linezolid continuous infusion
In the intervention arm, Linezolid is administered 600 mg as loading dose as an infusion lasting one hour (flow rate 300 ml/h), followed by continuous infusion of 1200 mg linezolid over 24 hours (flow rate 25 ml/h) which is immediately initiated. The continuous infusion is administered until the end of the treatment.
Linezolid continuous infusion
Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
Linezolid Intermittent administration
In the comparator arm, 600 mg dose of Linezolid is administered as one-hour infusion (flow rate 300 ml/h). Two doses at 12-h intervals are infused until the end of the treatment.
Linezolid continuous infusion
Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Linezolid continuous infusion
Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* female or male sex,
* age over 18 years,
* linezolid is prescribed by the attending physician, in empirical treatment or based on the antibiogram.
Exclusion Criteria
* no informed consent signed
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iuliu Hatieganu University of Medicine and Pharmacy
OTHER
Cluj Municipal Clinical Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bodolea Constantin
Assoc Prof. Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Constantin Bodolea, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca
Ligia A Hui, PharmD
Role: PRINCIPAL_INVESTIGATOR
University Of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca
Adina Popa, Prof PharmD
Role: STUDY_CHAIR
University Of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca
Laurian Vlase, Prof, PharmD
Role: STUDY_CHAIR
University Of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Clinical Municipal Hospital
Cluj-Napoca, Cluj, Romania
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hui LA, Bodolea C, Vlase L, Hiriscau EI, Popa A. Linezolid Administration to Critically Ill Patients: Intermittent or Continuous Infusion? A Systematic Literature Search and Review. Antibiotics (Basel). 2022 Mar 24;11(4):436. doi: 10.3390/antibiotics11040436.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.